Crohn's disease is a long-term illness that causes swelling in the digestive tract, often in the bowels. It can lead to symptoms like belly pain, diarrhea, tiredness, and weight loss. Not all treatments work for everyone, and they might stop working over time. This study tests new targeted therapies (TaTs) for adults with moderate to severe Crohn's disease. The medications being tested are risankizumab, ABBV-382, and lutikizumab. These are given as shots under the skin or through a drip into the vein.

When you join, you will be randomly assigned to a treatment group. The study has three parts: a 12-week starting period, a 12-week maintenance period, and an optional long-term part. About 500 adults will join the study at 300 sites worldwide. You will visit the hospital or clinic regularly for check-ups, blood tests, and other assessments.

• The study involves regular hospital visits and tests.
• The study lasts for at least 24 weeks, with an option to continue longer.
• There may be more treatment burden compared to usual care.